Cargando…

Last but not least: BFL-1 as an emerging target for anti-cancer therapies

BFL-1 is an understudied pro-survival BCL-2 protein. The expression of BFL-1 is reported in many cancers, but it is yet to be clarified whether high transcript expression also always correlates with a pro-survival function. However, recent applications of BH3-mimetics for the treatment of blood canc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Gaoyuan, Diepstraten, Sarah T., Herold, Marco J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Portland Press Ltd. 2022
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444066/ https://www.ncbi.nlm.nih.gov/pubmed/35900226 http://dx.doi.org/10.1042/BST20220153

Ejemplares similares

A1/Bfl-1 in leukocyte development and cell death
por: Ottina, Eleonora, et al.
Publicado: (2012)

A redox switch regulates the structure and function of anti-apoptotic BFL-1
por: Korshavn, Kyle J., et al.
Publicado: (2020)

Removal of BFL-1 sensitises some melanoma cells to killing by BH3 mimetic drugs
por: Gangoda, Lahiru, et al.
Publicado: (2022)

hBfl-1/hNOXA Interaction Studies Provide New Insights on the Role of Bfl-1 in Cancer Cell Resistance and for the Design of Novel Anticancer Agents
por: Barile, Elisa, et al.
Publicado: (2016)

Anti-Apoptotic Bfl-1 Is the Major Effector in Activation-Induced Human Mast Cell Survival
por: Ekoff, Maria, et al.
Publicado: (2012)

The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-κB activity and down-regulating Bfl-1
por: Kim, Min-Kyoung, et al.
Publicado: (2011)

The Emerging Importance of Mitochondria in White Adipocytes: Neither Last nor Least
por: Cai, Juan, et al.
Publicado: (2023)

Bfl-1 gene expression in breast cancer: its relationship with other prognostic factors.
por: Yoon, Ho-Sung, et al.
Publicado: (2003)

Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1
por: Jenson, Justin M, et al.
Publicado: (2017)

BCL-2 protein family: attractive targets for cancer therapy
por: Kaloni, Deeksha, et al.
Publicado: (2022)

Upregulation of bfl-1 is a potential mechanism of chemoresistance in B-cell chronic lymphocytic leukaemia
por: Olsson, A, et al.
Publicado: (2007)

BFL-1 expression determines the efficacy of venetoclax in MYC+/BCL2+ double hit lymphoma
por: Esteve-Arenys, Anna, et al.
Publicado: (2018)

BFL: a node and edge betweenness based fast layout algorithm for large scale networks
por: Hashimoto, Tatsunori B, et al.
Publicado: (2009)

Differential effects of Vav‐promoter‐driven overexpression of BCLX and BFL1 on lymphocyte survival and B cell lymphomagenesis
por: Tuzlak, Selma, et al.
Publicado: (2018)

SARS: at least and at last, are we learning from the worst?
por: Gonzalez, Jean-Paul J.
Publicado: (2003)

COVID-19 in an inequitable world: the last, the lost and the least
por: Tan, Mark K I
Publicado: (2021)

BFL1 modulates apoptosis at the membrane level through a bifunctional and multimodal mechanism showing key differences with BCLXL
por: Flores-Romero, Hector, et al.
Publicado: (2018)

Ds tagging of BRANCHED FLORETLESS 1 (BFL1) that mediates the transition from spikelet to floret meristem in rice (Oryza sativa L)
por: Zhu, Qian-Hao, et al.
Publicado: (2003)

The anti-apoptotic Bcl-2 family protein A1/Bfl-1 regulates neutrophil survival and homeostasis and is controlled via PI3K and JAK/STAT signaling
por: Vier, J, et al.
Publicado: (2016)

Multiple Myeloma Relapse Is Associated with Increased NFκB Pathway Activity and Upregulation of the Pro-Survival BCL-2 Protein BFL-1
por: Spaan, Ingrid, et al.
Publicado: (2021)

Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B
por: Rooswinkel, R W, et al.
Publicado: (2012)

The Last Common Ancestor of Most Bilaterian Animals Possessed at Least Nine Opsins
por: Ramirez, M. Desmond, et al.
Publicado: (2016)

Virotherapy: cancer gene therapy at last?
por: Bilsland, Alan E., et al.
Publicado: (2016)

µ-Calpain Conversion of Antiapoptotic Bfl-1 (BCL2A1) into a Prodeath Factor Reveals Two Distinct alpha-Helices Inducing Mitochondria-Mediated Apoptosis
por: Valero, Juan García, et al.
Publicado: (2012)

Heme oxygenase-1: emerging target of cancer therapy
por: Chau, Lee-Young
Publicado: (2015)

The Mu strain: the last but not least circulating ‘variant of interest’ potentially affecting the COVID-19 pandemic
por: Rahimi, Farid, et al.
Publicado: (2021)

Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy
por: Liu, Tongyan, et al.
Publicado: (2019)

Injectable Hydrogels for Cancer Therapy over the Last Decade
por: Cirillo, Giuseppe, et al.
Publicado: (2019)

Emerging Anti-Atherosclerotic Therapies
por: Gluba-Brzózka, Anna, et al.
Publicado: (2021)

Defueling the cancer: ATP synthase as an emerging target in cancer therapy
por: Wang, Ting, et al.
Publicado: (2021)

The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer
por: Denaro, Nerina, et al.
Publicado: (2013)

COVID‐19: Omicron – the latest, the least virulent, but probably not the last variant of concern of SARS‐CoV‐2
por: Brüssow, Harald
Publicado: (2022)

Targeting mTOR for Anti-Aging and Anti-Cancer Therapy
por: Fu, Wencheng, et al.
Publicado: (2023)

Ferroptosis: An Emerging Target for Bladder Cancer Therapy
por: Shan, Zhengda, et al.
Publicado: (2023)

Death receptors as targets for anti-cancer therapy
por: Papenfuss, Kerstin, et al.
Publicado: (2008)

Endocrine therapy: defining the path of least resistance
por: Stone, Andrew, et al.
Publicado: (2014)

Targeted radionuclide therapy in endocrine-related cancers: advances in the last decade
por: Al-Toubah, Taymeyah, et al.
Publicado: (2023)

Emerging strategies to target RAS signaling in human cancer therapy
por: Chen, Kun, et al.
Publicado: (2021)

Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance
por: Staudt, Dilana, et al.
Publicado: (2018)

Potential of Anti-MUC1 Antibodies as a Targeted Therapy for Gastrointestinal Cancers
por: Bose, Mukulika, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s248m2nbuds12s17qhqjpfmu6a